Bafna PharmaceuticalsNSE:BAFNAPH +5.00%59 Quick Ratio is 1.06 as of Mar. 2026, which is 7% below its 10-year median of 1.14. GuruFocus rates NSE:BAFNAPH with a GF Score™ of 59/100 and a GF Value™ of ₹90.56 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 997 Drug Manufacturers companies, Bafna Pharmaceuticals ranks worse than 63.29% on this metric.
Bafna Pharmaceuticals has a quick ratio of 1.06. It generally indicates good short-term financial strength.
The historical rank and industry rank for Bafna Pharmaceuticals's Quick Ratio or its related term are showing as below:
NSE:BAFNAPH'
s Quick Ratio Range Over the Past 10 Years
Min: 0.55 Med: 1.14 Max: 1.43
Current: 1.06
During the past 13 years, Bafna Pharmaceuticals's highest Quick Ratio was 1.43. The lowest was 0.55. And the median was 1.14.
NSE:BAFNAPH's Quick Ratio is ranked worse than 63.29% of 997
companies
in the Drug Manufacturers industry
Industry Median: 1.45
vs NSE:BAFNAPH: 1.06
Bafna Pharmaceuticals (NSE:BAFNAPH) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Bafna Pharmaceuticals Quick Ratio Related Terms
Bafna Pharmaceuticals Quick Ratio Historical Data
* Premium members only.
The historical data trend for Bafna Pharmaceuticals's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bafna Pharmaceuticals's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bafna Pharmaceuticals Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bafna Pharmaceuticals's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Bafna Pharmaceuticals's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Bafna Pharmaceuticals's Quick Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bafna Pharmaceuticals (NSE:BAFNAPH) has a Quick Ratio of 1.06 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Bafna Pharmaceuticals and its competitors. This is near median its historical median of 1.14. Over the past decade, Bafna Pharmaceuticals' Quick Ratio has ranged from 0.55 to 1.43. According to the industry distribution chart, Bafna Pharmaceuticals ranks #631 out of 997 companies in the Drug Manufacturers industry, placing it in the top 63.3%.
Is Bafna Pharmaceuticals' Quick Ratio too high?
Bafna Pharmaceuticals' current Quick Ratio of 1.06 is near median its 10-year median of 1.14. Over the past 10 years, this metric has ranged from a low of 0.55 to a high of 1.43. The Drug Manufacturers industry median Quick Ratio is 1.45. Bafna Pharmaceuticals' value of 1.06 is 26.9% below this industry median. Based on the distribution chart, Bafna Pharmaceuticals ranks #631 out of 997 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Bafna Pharmaceuticals has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bafna Pharmaceuticals' Quick Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Bafna Pharmaceuticals ranks #631 out of 997 companies for Quick Ratio. This places Bafna Pharmaceuticals in the lower half of its industry. The industry median Quick Ratio is 1.45. Bafna Pharmaceuticals' value of 1.06 is 26.9% below this benchmark. Historically, Bafna Pharmaceuticals' own Quick Ratio has ranged from 0.55 to 1.43 over the past decade. While the company's 10-year median is 1.14 vs. the industry median of 1.45, Bafna Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.45, based on 997 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bafna Pharmaceuticals's current Quick Ratio of 1.06 is 26.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Bafna Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bafna Pharmaceuticals's current Quick Ratio is 1.06, which is near median its own 10-year median of 1.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bafna Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Bafna Pharmaceuticals (NSE:BAFNAPH) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹90.56, compared to a current price of ₹194.68 — trading 115% above its estimated fair value. The current Quick Ratio is 1.06, which is near median its 10-year median of 1.14 and 26.9% below the Drug Manufacturers industry median of 1.45. Bafna Pharmaceuticals' overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Bafna Pharmaceuticals (NSE:BAFNAPH), the current Quick Ratio is 1.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bafna Pharmaceuticals (NSE:BAFNAPH) Overvalued in 2026?
Based on GuruFocus' analysis, Bafna Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹194.68 is trading 115% above its estimated GF Value™ of ₹90.56.
GuruFocus considers Bafna Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for NSE:BAFNAPH:
Quick Ratio: 1.06 (near median its 10-year median of 1.14)
GF Value™: ₹90.56 vs. price of ₹194.68 (115% above fair value)
Industry Position: 26.9% below the Drug Manufacturers median (#631 of 997)
No single metric tells the full story. See the NSE:BAFNAPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bafna Pharmaceuticals Ltd is an Indian pharmaceutical company mainly offering Contract Research and Manufacturing (CRAMS), Technology Transfers, Formulation, and Analytical Development services. It is engaged in the business of manufacturing finished pharmaceutical formulations, specializing in non-betalactam solid oral dosage forms, besides other emerging and potential products and forms in various therapeutic areas such as cardiology, lifestyle and potent drugs, and pain management. The company delivers generic pharmaceutical products for the UK, Australia, the EU, and emerging markets. In addition, it has launched its own brands in Sri Lanka, the Philippines, Tanzania, and Nigeria, offering products for some high-demand therapies like diabetes, cardiovascular, and oncology.
59GF Score
Get the complete analysis for NSE:BAFNAPH
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BAFNAPH has been successfully added to your 
